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Preoperative thrombolysis and venoplasty affords
no benefit in patency following first rib resection
and scalenectomy for subacute and chronic
subclavian vein thrombosis
James Lawrence Guzzo, MD, Kevin Chang, BA, Jasmine Demos, CRNP, CPNP, James H. Black, MD,
and Julie A. Freischlag, MD, Baltimore, Md
Background: Axillosubclavian vein thrombosis, also known as Paget-Schroetter syndrome, is a rare presentation of
thoracic outlet syndrome (TOS) representing approximately 5% of all cases. Conventional management consists of
routine anticoagulation, operative decompression via first rib resection and scalenectomy (FRRS), and, recently,
thrombolysis. The purpose of our study was to retrospectively review our experience with this condition and compare the
effectiveness of preoperative endovascular intervention with thrombolysis and venoplasty to anticoagulation alone in
those undergoing FRRS to preserve subclavian vein patency.
Methods: A retrospective review was conducted for all venous TOS patients from July 2003 to May 2009 from a
prospectively maintained database. Preoperative clinic notes were reviewed to allow stratification into two groups. One
group consisted of patients undergoing preoperative endovascular intervention with thrombolysis and venoplasty, while
the other group consisted of patients managed medically with anticoagulation alone prior to FRSS. Operative notes,
postoperative venograms, and postoperative duplex imaging results were reviewed for presence of recanalization, chronic
nonocclusive thrombus, or continued occlusion.
Results:One hundred three patients had 110 FRRS for subclavian vein thrombosis (53 men, 50 women), seven of which
had contralateral FRRS for thrombosis. The cohort averaged 31 years of age (range, 16-54 years) with an overall, mean
follow-up time of 16 months (range, 1-52 months). Of the 110 veins evaluated, 45 underwent endovascular intervention
(thombolysis, with or without venoplasty) prior to FRRS, and at 1 year, 41 (91%) were patent with improvement of
symptoms. In the 65 veins on anticoagulation alone, 59 (91%) ultimately were patent, with symptomatic improvement in
all. Overall, 91% (100/110) of subclavian veins were patent in patients completing follow-up, were asymptomatic, and
back to their previous active lifestyle.
Conclusions: Preoperative endovascular intervention offered no benefit over simple anticoagulation prior to FRRS, since
the use of thrombolysis prior to FRRS, regardless of need for postoperative venoplasty, had little impact on overall rates
of patency. The optimal treatment algorithm may merely be routine anticoagulation for all effort thrombosis patients
prior to FRRS followed by venography with venoplasty if needed. The role of thrombolysis for Paget-Schroetter
syndrome should be further investigated in randomized trials. ( J Vasc Surg 2010;52:658-63.)Effort thrombosis of the axillosubclavian vein was first
reported by Sir Paget in 1875 and Von Schroetter in 1884,
and was coined “Paget-Schroetter syndrome” by Hughes
in 1949.1 The syndrome is a rare presentation, accounting
for 5% of all cases of thoracic outlet syndrome (TOS), a
compression phenomena of the neurovascular structure of
the shoulder.2,3 It is mostly seen in active and athletic
individuals, and results from repetitive upper extremity
motion. Historically, treatment for this syndrome consisted
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658of arm elevation and routine anticoagulation. The current
treatment paradigm of thrombolysis followed by 3 months
of anticoagulation therapy, and subsequent operative de-
compression by first rib resection and scalenectomy (FRRS)
was initially described by Machleder.4-6 Modifications of
this treatment paradigm have been reported, with Urschel
and Razzuk being the first to report early FRRS following
thrombolysis with good results; other groups have reported
similar outcomes with early operative decompression.7-9
Our group described combining thrombolysis and FRRS in
one hospitalization with excellent results.10
Our institution is a referral center for all types of
thoracic outlet patients, and as such, has extensive experi-
ence with this syndrome across a broad spectrum of severity
and at variable time points in a patient’s treatment. Because
we see patients at such variable time points, we treat those
who have been referred with the only treatment being
anticoagulation, while others may be seen after multiple
endovascular interventions. Consequently, we were able to
recently report multiple treatment algorithms for venous
TOS with regard to variable utilization of thombolysis,
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tive decompression via FRRS, and found excellent axillo-
subclavian vein patency rates.11 The purpose of the present
study was to retrospectively review this extensive experience
with venous TOS and compare the effectiveness of preop-
erative endovascular intervention with thrombolysis and
venoplasty with anticoagulation alone in those undergoing
FRRS to preserve axillosubclavian patency.
PATIENTS AND METHODS
A retrospective review was conducted for all venous
TOS patients from July 2003 to May 2009 from a prospec-
tively maintained database. Preoperative clinic charts were
evaluated with age, gender, antecedent upper extremity
injury, contralateral involvement, presence of serologically
documented hypercoagulable state, and any prior imaging
results recorded. In addition, utilization of preoperative
medical management with anticoagulation, thrombolysis,
or thrombolysis with percutaneous venoplasty was re-
corded.
FRRS was performed via a transaxillary approach in all
patients, as previously described. Following FRRS, images









Duplex ultrasound 15 (33%) 41 (63%)
Venogram 26 (57%) 14 (21%)
Computed tomography 3 (7%) 6 (9%)
MRV 1 (2%) 4 (6%)
Angiogram 1 (2%) 0





Males (total 53) 29 (55%) 24 (45%)
Females (total 50) 16 (32%) 34 (68%)
Hypercoagulable disorder 3 (7%) 5 (8%)




Sports injury 20 (44%) 25 (38%)
Occupational 12 (27%) 14 (22%)
MVC/fall 1 (2%) 2 (3%)
Musician 2 (4%) 3 (5%)
Cervical rib 1 (2%) 0 (0%)
Unknown 9 (20%) 21 (32%)


















FRRS, First rib resection and scalenectomy; JHH, Johns Hopkins Hospital;
MRV, magnetic resonance venography; MVC, motor vehicle collision.and reports of 2-week follow-up venograms were reviewedand recorded with regard to axillosubclavian vein patency,
need for percutaneous venoplasty, results of that interven-
tion, presence of lesions that failed intervention (occlu-
sions), and use of ongoing anticoagulation. Follow-up
clinic evaluations were reviewed for patient symptoms and
duration of anticoagulation, and duplex imaging was re-
viewed for presence of recanalization, chronic nonocclusive
thrombus, or complete occlusion.
RESULTS
One hundred three patients were identified from our
prospectively maintained database that had 110 FRRSs for
subacute and chronic subclavian vein thrombosis (Table I).
Seven patients had contralateral FRRS for thrombosis. No
patients presented with acute limb threat or phlegmasia.
The cohort averaged 31 years of age (range, 16-54 years)
with a mean follow-up time of 16 months (range, 1-63
months). Eight patients (8%) had documented hyperco-
agulability by serologic testing at facilities prior to entrance
into our system; the most common was Factor V Leiden
mutation (three patients). The majority of patients in the
preoperative intervention group had venography as the
initial diagnostic imaging modality (57%), while in the
group managed medically with anticoagulation alone, du-
plex ultrasound was the imaging study of choice (63%).
Sports injuries were the most common antecedent injury in
both groups, followed by occupational injuries.
Overall, 45 veins (41%) underwent preoperative endo-
vascular interventions prior to FRRS, while 65 (59%) were
managed with anticoagulation alone prior to operative
therapy with FRRS (Table II). The patients with veins
undergoing preoperative intervention with thrombolysis
and venoplasty were evaluated in clinic an average of 3.8
months from their initial event and presentation to a med-
ical provider (range, 1-24 months), reflecting the widely
variable entry point of patients into our system. They
underwent FRRS an average of 1.6 months from the first
encounter in our clinic (range, 1-10 months) and had









Lovenox 7 (16%) 2 (3%)
Lovenox/warfarin 5 (11%) 4 (6%)
Warfarin 26 (58%) 35 (54%)
Heparin gtt 1 (2%) 1 (2%)









None 7 (16%) 16 (25%)
aCompleted course prior to evaluation at our institution.follow-up at a mean of 20 months (Table I).
nd sca
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tions prior to operative decompression, 25 (56%) had
thombolysis alone, and 20 (44%) had thrombolysis and
axillosubclavian balloon venoplasty (Table I). Seven pa-
tients had thrombolysis at our facility. Following FRRS at
our institution, 43 (96%) veins that underwent preopera-
tive intervention had follow-up venograms per our proto-
col 2 weeks postoperatively; two patients were immediately
lost to follow-up (and were included in the analysis as being
occluded). The venograms revealed a widely patent subcla-
vian vein in 15 (35%), stenosis requiring balloon dilatation
in 21 (49%), and seven occlusions (16%). Occlusions were
defined as veins harboring a lesion that could not be crossed
with a wire at the time of the venogram. Veins that were
occluded on venogram were maintained on warfarin for 6
months or until patency was restored as seen on follow-up
duplex ultrasound. The overall initial patency rate in this
groupwas 84%. Two patients had early re-thrombosis (30
days) and had repeat lysis and venoplasty with immediate
restoration of patency and follow-up duplex demonstrating
the same. During the follow-up period, five of the seven
occlusions were documented to be recanalized by duplex
exam with restoration of the patency of the subclavian vein
at a mean of 2.8 months postoperatively (range, 1-6
months). Each patient had improvement in symptoms.
One patient was lost to follow-up and one remained oc-
cluded with minor symptoms.
The 65 patients managed medically with anticoagula-
tion alone were evaluated in clinic an average of 6.2 months
from their inciting event (range, 1-72 months) and under-
went FRRS an average of 2.1 months from our clinic
encounter (range, 1-10months). In this cohort of 65 veins,
61 (94%) underwent follow-up venograms. Four patients
were lost to follow-up after FRRS and were assumed oc-
cluded in the final analysis. The venograms revealed 15
(23%) patent subclavian veins and stenosis of the subclavian
vein requiring balloon dilatation in 36 (55%) veins. Three
patients had veins re-thrombose in the early follow-up
Fig. One hundred ten first rib resection aperioperative period (30 days), were lysed, renderedpatent, and remained that way at first follow-up duplex exam
at 2months. Ten subclavian veins (16%)were occluded. Eight
of 10 (80%) subclavian vein occlusions were documented to
be recanalized by duplex exam at an average of 4.3 months
(range, 1-11 months) following FRRS. All patients had reso-
lution of symptoms, except one of the two remaining oc-
cluded veins. The average follow-up was 14.5 months and
ranged from 2 months to 3 years (Table I).
Utilization of anticoagulation varied as the patients
entered our systems at various points in the time course of
their care and were referred from all over the country (Fig).
Warfarin was the predominant anticoagulant of choice,
with 58% of patients who underwent preoperative interven-
tion arrived to our clinic on this agent compared with 54%
of patients managed on anticoagulation alone. Thirty-five
percent of the patients in the medically managed group
entered our system on no anticoagulation at all, having
completed a 3- to 6-month course prior to arrival. Follow-
ing FRRS, 38 (84%) veins in the preoperative intervention
group remained on warfarin for an average of 2.88 months
(range, 0-6 months), at which time point veins were con-
sidered patent. In the anticoagulation-alone group, 49
(75%) veins remained on warfarin in the follow-up period
for an average of 2.55 months (range 0-13 months), with
patients ceasing its use when subclavian veins were shown
to be patent on dupex scan with abduction and adduction
maneuvers.
DISCUSSION
If available, the standard, step-wise treatment of effort
thrombosis is thrombolytic therapy, anticoagulation, FRRS,
and postoperative venoplasty as required. Not all institutions
have advanced endovascular capabilities or familiarity with this
diagnosis or approach, and instead begin anticoagulation
therapy alone. As a major referral center, we, as a result, see
patients who enter our system at extremely varied time points
after both treatmentmodalities.However, whatwe are able to
see is that what appears to be most critical is relief of extrinsic
lenectomy (FRRS) for effort thrombosis.compression on the axillosubclavian vein by FRRS. What this
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variable degrees of venous stenosis and thrombus may be
subsequently treated successfully with anticoagulation and
endovascular technology. Following rib resection, the timing
of these interventions has been under investigation in the
recent literature, and is controversial.
Traditional therapy for effort thrombosis with immedi-
ate thrombolysis, followed by anticoagulation and subse-
quent first rib resection, scalenectomy, and subclavius ten-
don division was first championed by Machleder. The
endovascular intervention was followed with routine Cou-
madin anticoagulation for a period of 3months, then FRRS
via a transaxillary approach was performed with excellent,
durable results.5,6 Subsequent authors have shortened or
eliminated the interval to operative decompression without
sacrificing safety or patency. The first report by Angle and
colleagues demonstrated strong results with early venogram,
thrombolysis, and FRRS without waiting through a 3-month
anticoagulation period.8Molina and colleagues reported sim-
ilar findings, noting 100% long-term subclavian vein patency
in 114 patients treated with immediate thrombolysis and
operation within 2 weeks of symptoms as compared with a
29% patency rate in patients treated after a more lengthy
interval.12 Our group detailed an algorithm that unified
treatment of axillosubclavian effort thrombosis in a single
hospital admission.10
The current treatment paradigm at our institution has
been to offer FRRS once the patient enters our system with
a clinical picture consistent with effort thrombosis. Because
of the variable entry point of these patients into our care, we
see patients who are being treated with anticoagulation
alone, or those who have undergone thrombolysis and are
maintained on anticoagulation. Our protocol calls for FRRS,
resuming anticoagulation postoperatively, and undergoing
venography 2 weeks postoperatively to identify subclavian
vein pathology that may require additional endovascular in-
tervention. Those that are identified as patent are told to stop
anticoagulation, while those requiring venoplasty are main-
tained on anticoagulation until follow-up imaging with du-
plex demonstrates vein patency.
In a recent article, Schneider et al13 described 25 pa-
tients with acute presentations, the majority of which un-
derwent immediate thrombolysis followed by subsequent
FRRS combined with intraoperative venography and per-
cutanteous venoplasty in a single combination treatment.
Sixteen of their patients (64%) had lesions amenable to
percutaneous intervention, all underwent venoplasty, and
had an overall long-term patency rate of 92%. By utilizing
this intervention during the operative decompression pro-
cedure, they were able to eliminate the routine use of
postoperative anticoagulation.
The need for long-term anticoagulation can obviously
be affected by the presence of patients with underlying
hypercoagulable disorders. In our series, a documented
hypercoagulable state was identified in 8% of the cohort.
This is similar to a study by Heron in which he investigated
the incidence of hypercoagulable states in upper extremity
effort thrombosis in 51 patients and found an incidence of6%, and concluded that the presence of coagulopathy is not
a contributing factor in causing effort-related thrombo-
sis.14 Patients in our series with hypercoagulable disorders
remain on indefinite anticoagulation therapy and have
long-term follow-up arranged with hematology. Over one-
third of the entire cohort had screening for hypercoagula-
ble disorders, something we do not routinely do at our
institution unless a clot occurs without a history of antecen-
dent work-related or sports-related injury.
Nevertheless, because of the broad distribution of pa-
tients entering our system with or without previous endo-
vascular intervention prior to our FRRS, we were able to
compare subclavian vein patency between these two groups
up to 1 year. Of the 110 patients evaluated, 45 underwent
endovascular intervention (thombolysis, with or without
venoplasty) prior to FRRS, and, at 1 year, 41 (91%) were
patent with improvement of symptoms. In the 65 patients
who entered our system on anticoagulation alone, 59 (91%)
ultimately were rendered free of thrombus or occlusion in
the study period, with symptomatic improvement in all.
The need for venoplasty at 2-week follow-up venograms
were similar, regardless of use of preoperative thrombolysis
or simple anticoagulation (21 of 43 [49%] in preoperative
intervention group, 36 of 61 (59%) in anticoagulation
group). The use of thrombolysis prior to FRRS, regardless
of need for postoperative venoplasty, had little impact on
overall rates of patency. And in regards to postprocedure
venograms, it must be emphasized that this is a disorder of
venous pathology, and a perfect angiographic result is not
needed as when dealing with arterial disease. We also feel
the use of stents in this position is a detriment to the patient
and should be avoided, as we have recently seen several of
these referred to our institution prior to FRRS and outside
of this study period. All have been occluded.
It is also interesting to note that seven patients in the
preoperative endovascular intervention group had occlu-
sions, while 10 in the anticoagulation group had occlu-
sions; with continued anticoagulation, five of seven in the
first group (71%; five patent on duplex, one occlusion, one
lost to follow-up) and eight of 10 in the anticoagulation
group (80%) recanalized during the follow-up period. So
despite the relatively low, but nearly equal number of
occlusions in both groups (despite differing preoperative
regimens and similar postoperative therapy), a similar per-
centage had duplex imaging evidence of recanalization over
time, and none of had ongoing symptoms through this
period. Patients may be reassured that FRSS may continue
to accrue symptom benefit for the long term.
There are several important limitations to our study.
The retrospective nature of our investigation is obviously
inferior to a properly blinded, prospective, randomized
controlled trial. Ideally, every patient encountered would
have a diagnostic venogram and be placed into an interven-
tion group and an anticoagulation-alone group and fol-
lowed thereafter. We have a limited ability to completely
ensure our two study groups; their history, thrombus bur-
den, and time course are completely comparable. Second,
patient demographics and comorbid conditions cannot be
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in the duration and type of anticoagulation as well as
endovascular treatments offered by the many endovascular
interventionalists prior to patients coming to our care.
Fourth, we are hampered by a relatively short follow-up
interval. And finally, even though we have the largest
prospective database with regard to TOS, wemay only have
outcomes from which we can demonstrate clinical observa-
tions but understandably lack the statistical power to make
definitive claims that a well-designed, randomized, con-
trolled trial affords.
But the very nature of this variability of our patients’
clinical picture and initial treatment may in fact strengthen
the notion that this treatment, be it thombolysis or simple
anticoagulation, has little impact on obtaining a successful
outcome following operative decompression. In addition,
it does not seem that in a relatively young and active patient
population, evaluation and stratification for cardiovascular
risk factors and comorbidities would confound data gener-
ated to compare treatments in a venous compression phe-
nomena. The short follow-up interval may not have large
clinical impact, as we have had very few overall patients lost
to follow-up (6% of total cohort), and we have had no
patients reocclude at distant time points in our care among
the 103 treated. What our retrospective data do suggest is
that a prospective, randomized controlled trial should be
performed to validate what could be a meaningful change
in the current treatment paradigm for subacute and chronic
effort thrombosis patients.
CONCLUSIONS
Preoperative endovascular therapy with thombolysis
and possible venoplasty offered no overall benefit in pa-
tients with subacute and chronic effort thrombosis, or
Paget-Schroetter syndrome. In this series, 41% of patients
underwent endovascular intervention prior to operative
decompression with FRRS, but showed no improvement in
outcome as determined by vein patency on postoperative
venography, follow-up duplex ultrasound, and symptom res-
olution versus anticoagulation alone. As such, the optimal
treatment algorithm may merely be routine anticoagulation
for all subacute and chronic effort thrombosis patients prior
to FRRS followed by venography with venoplasty as
needed. Liberal use of anticoagulation for those who have
had venoplasty and have a vein occlusion also plays an
important role in the vein remaining patent. Overall, 91%
of patients in each group have patent subclavian veins by
duplex scan and are back to their previous active lifestyle.
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Dr L. Richard Sprouse (Chattanooga, Tenn). Thank you.
First of all, I would like to thank the authors for providing me
with this manuscript before the meeting. I haven’t noticed any
major changes compared to the original abstract that was sub-
mitted to the Southern Association for Vascular Surgery, and I
would like to congratulate Dr Guzzo on an outstanding presen-Dr Guzzo and colleagues present a retrospective analysis of
more than 100 patients presenting with axillosubclavian venous
thrombosis related to venous thoracic outlet syndrome. The pur-
pose of the paper was to compare the effectiveness of thrombolysis
and PTA with anticoagulation alone in those patients undergoing
FRRS to preserve subclavian vein patency. The authors conclude
that preoperative thrombolysis doesn’t improve subclavian vein
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able results and may lead to significant cost savings. Based on
previous reports from their institution and others, I adopted an
aggressive approach over the past several years in managing pa-
tients with effort thrombosis. All patients presenting with subcla-
vian vein thrombosis for TOS at my institution undergo immediate
thrombolysis, percutaneous thrombectomy, and angioplasty fol-
lowed by early transaxillary first rib resection.
The severity of symptoms in the patients presented by Dr
Guzzo was not clearly stated in the manuscript, but many of the
patients I encounter with venous TOS present with debilitating
symptoms, and early intervention in these patients provides signif-
icant symptomatic relief and facilitates a quick recovery. Many of
the patients in the current study also underwent early intervention
with thrombolysis; however, it is not clearly stated in the manu-
script why some patients were treated only with anti-coagulation.
In addition, many of the patients had undergone interventions at
other facilities prior to presentation but the manuscript does not
provide the details of these procedures and does not state which
patients received prior treatment. Although the demographics of
the two study groups described by the authors appear similar,
comparing the groups in regards to the patency of the subclavian
vein appears hazardous withoutmore information regarding which
patients received which intervention during what time period and
for what reason. I have several questions for the authors:
1. Can you describe what defined a patient as being symptomatic
at the time of presentation?
2. Do you have an idea of the severity of the symptoms and, if so,
how did this influence the initial treatment recommendations?
3. Can you provide the details regarding the initial venoplasty
procedure? What was the typical ballon size? Did you use
cutting balloons or any other local therapies? And did any of
the patients have percutaneous thrombectomy in addition to
thrombolysis?
4. You stated that 45 patients had thrombolysis alone or throm-
bolyis  PTA prior to FRSS. Were all of these procedures
successful in restoring patency of the vein? And of the seven
occlusions that occurred postoperatively, how many of these
only had thrombolysis at the initial procedure?
5. Finally, you report that despite the failure to cross many of these
lesions and reopen the vein, more than 80% of the occluded
subclavian veins had recanalized and were patent on follow-up
ultrasound, and the patients were asymptomatic. Do you think
this argues for a more selective approach to performing the
2-week venogram and potentially eliminating it as an additional
cost-saving measure?
Again, I would like to congratulate the authors on an out-
standing presentation and I am honored that the Southern Asso-
ciation for Vascular Surgery invited me to discuss this paper.
Dr James L. Guzzo (Baltimore, Md). Thank you very much;
those are all excellent questions. I will try to go down the list. As far
as defining symptoms, since the majority of the patients receive
initial evaluation at outside hospitals, the best we have is our first
clinic evaluation. We did go through all 100 patients’ clinic charts;sometimes when we see them it is a couple of weeks after that initial
event, and more rarely, a few months. Their symptoms run the
gamut, so as far as pinning them down and saying, “Did you have
an acute limb?” that obviously came back as “No.” But someone
with more severe symptoms in the dominant limb is oftentimes
more alarming to the patient and even to the treating physician
(more than something that happens in the leg), and this perception
may lead to the decision to perform thombolysis. Because such a
vast number were done at an outside hospital, it becomes a
potential study weakness because they weren’t all treated at our
institution. We cannot make that definitive claim where yes, the
arm looked terrible, they really deserve lytics, or yes, it is not so
bad, raise your arm and go home on Lovenox and you will feel fine
in a day.
As far as balloon size, typically we use an 8, 10, or 12 for serial
dilations almost routinely. We have even gone up to a 14 to 16 on
rare occasions. The venograms are performed in greater than 95%
by our staff in the vascular division. Those are the ones that I was
lucky to be involved with, so a majority used that series of balloons
in those with angiographic evidence of a greater than 50% stenosis
of the subclavian vein. Nobody was thrombectomized nor were
open or percutaneous/Angiojet-type systems utilized; nobody
received stents either. Outside of this cohort, since May 2009, we
have had several people referred who have been stented by outside
facilities prior to referral for rib resection, and they do terribly.
They are all occluded, and following first rib resection and scale-
nectomy, we still can’t get them open. Their outcomes are still in
evolution, and hopefully we will report on them at a later date, as
we think they have done poorly enough that that warrants some
investigation as well.
As far as patency after those procedures at an outside hospital,
we can only comment if we are lucky enough to get the operative
reports, as they come from all over the country. Unfortunately, I
don’t have numbers to say yes, that lytic therapy rendered their
subclavian vein patent or their balloon angioplasty rendered them
patent; however, anecdotally we do have a number of people who
do get lysed prior to our initial evaluation before rib resection and
scalenectomy, and on duplex are thrombosed again. We feel until
you get the rib out, you haven’t really treated anything. I would
probably agree to lysis for a big, uncomfortable dominant arm in
the acute setting, but for those with subacute and chronic throm-
boses, after thombolysis, within weeks they re-occlude again, so
anticoagulation and getting to a rib resection is critical.
As far as doing more “selective” venograms postoperatively,
that might be something we could look at and is an excellent point
we could follow up on; however, we feel fairly confident that the
2-week time point for the venogram really lets us know who can
and does not have to go on further anticoagulation therapies.
We think that is a very valuable part of our algorithm, and if
stenosis is encountered, we can balloon, and they do well.
Often-times, their anticoagulation duration is reduced as well
because of that venogram.Thank you all very much.
